Back to Search Start Over

Therapeutic Management of COVID-19 Patients

Authors :
Abdessamad Aglagane
Abdelaati El Khiat
Ahmed Draoui
Lahcen Tamegart
Halima Gamrani
Youssef Ait Hamdan
Radouane El Fari
Source :
Handbook of Research on Pathophysiology and Strategies for the Management of COVID-19
Publication Year :
2022
Publisher :
IGI Global, 2022.

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCov-2) or COVID-19 is a pandemic that appeared in December 2019 in China and which is an RNA virus. It gave rise to a major health crisis at the start of 2020, with numerous hospitalizations. It was quickly important to understand the pathophysiology of this viral attack on the human body in order to be able to develop treatment. However, there is no vaccine or effective therapeutic agent against SARS-CoV-2. Most of the therapeutic strategies used to deal with this virus come from the work of previous epidemics of SARS, and other influenza viruses, such as antiviral therapies (chloroquine, hydroxychloroquine), adjuvant therapies by combining antivirals with drugs. Antibiotics or immunostimulants (vitamins C, Dm and Zinc, etc,) and several other therapies to be used depending on the region.

Details

Database :
OpenAIRE
Journal :
Handbook of Research on Pathophysiology and Strategies for the Management of COVID-19
Accession number :
edsair.doi...........8b2ff5918de3fece58c69dac892edcb0
Full Text :
https://doi.org/10.4018/978-1-7998-8225-1.ch013